Liver Diseases  >>  oltipraz (PMK-N01GI1)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
NCT02068339: Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis

Completed
3
283
RoW
Oltipraz 1 (90mg), Placebo, Oltipraz 2 (120mg)
PharmaKing
Non-alcholic Fatty Liver Disease
02/16
03/16

Download Options